The digital intermediary platform for clinical studies brings together all participants i.e. patients, doctors, study centres and pharmaceutical companies conducting research. "We would already like to give patients today access to tomorrow's medicine", explains Viomedo founder Alexander Puschilov. Viomedo was established in Germany in 2015 and has about 100,000 registered patients. Pfizer Austria and Boehringer Ingelheim Regional Center Vienna (RCV are on board at the launch of the platform's activities in Austria.
Clinical studies comprise the centrepiece of medical progress. The people affected rely on the development of new treatment methods. By participating in clinical studies, they can gain access earlier to new therapies which are not yet available on the marketplace. The pharmaceutical industry alone carries out about 470 clinical studies in Austria each year. However, there is no simple and transparent possibility for patients to find suitable clinical studies in which they can take part.